Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFNα-Kinoid in SLE
NCT01058343Phase 2Completed
- Sponsor
- Neovacs
- Start
- Mar 2010
- Primary completion
- Apr 2011
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of IFN-K in systemic lupus erythematosus (SLE) (5 arms), sponsored by Neovacs. Primary endpoint: Frequency and severity of adverse events. Started Mar 2010; status: completed.
02
Drugs
IFN-K
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01058343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01058343.